Roth Capital Remains Positive on Galena Biopharma (GALE) Following Zuplenz Launch
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- One killed, three injured when man attacks Swedish school with sword
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
Galena Biopharma (GALE) Announces U.S. Launch of Zuplenz
July 29, 2015 7:06 AM EDTGalena Biopharma (NASDAQ: GALE) announced the product launch for Zuplenz (ondansetron) Oral Soluble Film in the United States.
Zuplenz is now available nationwide and is supplied in both 4 mg and 8 mg strengths. Zuplenz is clinically bioequivalent to ondansetron orally disintegrating tablets (ODT) with a safety profile equivalent to ondansetron. The novel, PharmFilm® oral soluble film technology utilized by Zuplenz provides for convenient delivery and several key patient benefits including:
Rapidly dissolves in the mouth in about 10 secondsEliminates the burden of swallowing pills... More